Kulpreet barn

advanced heart failure Cardilogist . director of advance heart failure/ mechanical circulatory program. advance heart failure program developer .

[Eiran Gorodeski, MD, MPH @EiranGorodeski]

We found that advanced heart failure and transplant cardiologists are few in number and unevenly distributed across the United States, leaving many regions with limited access to specialized care. https://t.co/lUsu9Mhbw3 #ACC26 @HarringtonHVI

[Brett Sperry, MD @BrettSperryMD]

Congestion drives HF decompensation. Can an implantable IVC sensor safely guide care for 12 months?

In FUTURE-HF, ambulatory IVC-guided care was safe, accurate, and actionable, with improved congestion and fewer HF events. Supports a pivotal trial.

https://t.co/LcbDVZfTV1

[Marwan Jumean, MD @JumeanMarwan]

From #pressor support to #impella support in #cardiogenicshock—how stable #pMCS enables #prehabilitation in the #ICU Gym and changes the trajectory. 💪

[Kulpreet barn @KulpreetBarn]

@AndrewJSauer @drjohnm AHF cards actually spend a significant amount of time interacting with community. Most AHF programs have outreach clinics , CS transfer protocols and inpatient availability at there community based hospitals in there systems. we don’t sit in ivory towers waiting for pts :-)

[Gregg Fonarow MD @gcfmd]

⚖️ Want to review the economic value of HF therapies?

Find that here:

📖 Read the report ➡️ https://t.co/z0cObHYV3M…

📺 Watch the highlights ➡️ https://t.co/5Xqth9vH33

[Eiran Gorodeski, MD, MPH @EiranGorodeski]

Here are all AHFTC fellowship programs that offered spots in last 5 years, and # of fellows they matched. 13 programs trained 50% of fellows. #HFSA2025 Skewed uneven distribution. Mega centers train most of the field. Insufficient exposure to community and rural needs. Worrisome.

[Gregg Fonarow MD @gcfmd]

🚧 The total direct costs for individuals with HF are estimated to be $227 billion in the US

HF-related costs are projected to grow significantly:

🚨 total direct medical costs for individuals with HF could rise to $858 billion by 2050

🎯 prioritize HF prevention and Rx

[JHLT @TheJHLT]

ECMO is increasingly used a bridge to transplant. In this study of the UNOS database, use of #ECMO as a bridge to multiorgan #transplant was associated with increased 30 day mortality and decreased long-term survival @ElbertHeng @JW_MacArthur @StanfordCTSurg

🔗: https://t.co/De8EGrGrGC

[Ahmad Masri @MasriAhmadMD]

3 out of 7 newly diagnosed ATTR-CM patients that I saw in 1 day didnt have ATTR-CM (2 on therapy). Just really tough to interpret PYP scans with blood pooling, and due to cavity size and shape they simply appeared as myocardial uptake to those reading them.

That is why we are running REVEAL (Evuzamitide in suspected cardiac amyloidosis). Cant afford making such mistakes.

https://t.co/zZM8kr5vda

#CardioTwitter #CVNuc

[Ahmed Teebi, MD MPH MSc(Ox)🗝️ @Teebi_MD]

🧵Substrate-based vs. clinical VT ablation?!

In ischemic VT, should we pursue substrate mapping (sinus) vs. entrainment mapping (in VT) as ablation strategy?

VT recurrence at 12 months:
👉Substrate-based ablation 15%
👉 Clinical ablation 48%

VISTA Trial ⬇️
https://t.co/ONy5P7coQM

#Epeeps

[Gregg Fonarow MD @gcfmd]

@maybeadoc1983 @drbennisahmed @mvaduganathan @JavedButler1 SCD ⬇️ in HFrEF RCTs where GDMT mandated by trial protocol

In clinical practice, SCD, progressive HF☠️, and all-cause ☠️ all ⬆️ since massive gaps in use and dosing in GDMT + rising HF incidence (w/o age adjustment)

Want to save 100,000 lives a year?

Apply GDMT by protocol

[Kulpreet barn @KulpreetBarn]

What a great opportunity to learn from the best!

[Kulpreet barn @KulpreetBarn]

I am happy to announce today that I  have started as Medical Director of Heart Failure of Robert Wood Johnson Barnabas Health (RWJBH) system. I would like to thank the leadership at RWJBH for giving me the honor and privilege to serve this region. My home state of New Jersey!

[Kulpreet barn @KulpreetBarn]

@ReyentovichHFMD @nyulangone @yaleHFdoc @JasonKatzMD @KadoshBernard @ShalineRaoMD Hopefully we start seeing it as LVAD plus/ or transplant rather than “ vs” !

[Alex Reyentovich, MD @ReyentovichHFMD]

Excellent collaboration with the heart and kidney team ⁦⁦@nyulangone⁩ to combine an LVAD implant with xeno kidney giving our patient a chance at life. Thank you to our patient and her family as well as our close collaborator
⁦@KulpreetBarn⁩ https://t.co/CgMyYHeWWL

[Kulpreet barn @KulpreetBarn]

@ReyentovichHFMD @nyulangone This patient is very lucky to have the best team around her . No surprise she is doing so well. Congrats to the entire team @nyulangone

[Ivan Netuka @netuka_ivan]

We are pleased to inform that our DOT-HM3 Trial results in partnership between IKEM and The Brigham Harvard just got online! Our results suggest a safety signal of Apixaban use with the HM3 up to a 6-months time point in stable LVAD patients. https://t.co/98omoxGm2W

[Kulpreet barn @KulpreetBarn]

@ShashankSinhaMD @NavinKapur4 @manreetkanwar @JHMontfort10 @ReshadGaranMD @BurkhoffMd @JasonKatzMD Most advance centers are already doing this and add PA Catheter to guide therapy. What this trial really shows is that temporary MCS should be used early in the community and get these pts to local advance centers asap like left main or aortic dissection.

[Rakendu Jayasree Rajendran @RakenduJR]

Amazing talk by Dr. @KulpreetBarn on evolving landscape of HFpEF @ACPNJ1 24
Main takeaways:
🌟SGLT2i: Only GDMT drug in HFpEF with class 2a recommendation. Use them!
🌟Consider screening HFpEF patients for amyloid.

#DAPAHFtrial

[Kulpreet barn @KulpreetBarn]

46 LVAD implants at DHLC this year. Special thanks to our entire team for all their hard work. Looking forward to helping more patients in 2024 with this therapy! Also very thankful to our referring providers for trusting us with their patients .